Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography.

Objectives: To estimate the prevalence of clopidogrel non-response and identify its risk factors among Saudi patients. 

Methods: This cross-sectional study was conducted at Prince Sultan Cardiac Center, Riyadh, Kingdom of Saudi Arabia between January and June 2013, to assess the degree of platelet inhibition using the VerifyNow assay (Accumetrics, San Diego, CA, USA) after receiving clopidogrel standard loading dose. Clopidogrel resistance was defined as ≤15% platelet inhibition or greater than 213 P2Y12 reaction units (PRU).